(Q53025681)

10 May 2018

title

Prostate cancer stem-like cells proliferate slowly and resist etoposide-induced cytotoxicity via enhancing DNA damage response. (English)

1 reference

10 May 2018

0 references

Judy Yan

1

1 reference

10 May 2018

Damu Tang

series ordinal

2

1 reference

10 May 2018

language of work or name

English

0 references

publication date

20 August 2014

1 reference

10 May 2018

Experimental Cell Research

published in

1 reference

10 May 2018

volume

328

1 reference

10 May 2018

issue

1

1 reference

10 May 2018

page(s)

132-142

1 reference

10 May 2018

Current status of experimental therapeutics for prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Metastatic pancreatic cancer: emerging strategies in chemotherapy and palliative care

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Targeting the androgen receptor pathway in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Dysregulated expression of growth factors and their receptors in the development of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

GPNMB/OA protein increases the invasiveness of human metastatic prostate cancer cell lines DU145 and PC3 through MMP-2 and MMP-9 activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Salvage treatment in prostate cancer: a clinical approach

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The evolving concept of cancer and metastasis stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Tumour stem cells and drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Galiellalactone inhibits stem cell-like ALDH-positive prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Cancer stem cells in solid tumours: accumulating evidence and unresolved questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Identification of cancer stem cell-like cells from human epithelial ovarian carcinoma cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Brca1 breast tumors contain distinct CD44+/CD24- and CD133+ cells with cancer stem cell characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Lineage analysis of basal epithelial cells reveals their unexpected plasticity and supports a cell-of-origin model for prostate cancer heterogeneity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

CD133, Stem Cells, and Cancer Stem Cells: Myth or Reality?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Role of polyamines in p53-dependent apoptosis of intestinal epithelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The DNA damage response and cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Characterization of sphere-propagating cells with stem-like properties from DU145 prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Both ERK1 and ERK2 kinases promote G2/M arrest in etoposide-treated MCF7 cells by facilitating ATM activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Cancer stem cells: models and concepts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Progression through the G1‐phase of the on‐going cell cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Regulation of G1 phase progression by growth factors and the extracellular matrix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Growth factor-dependent signaling and cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Molecular regulation of stem cell quiescence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

N-cadherin mediates angiogenesis by regulating monocyte chemoattractant protein-1 expression via PI3K/Akt signaling in prostate cancer cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Akt signaling and cancer: surviving but not moving on.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Etoposide in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Therapeutic options for hormone-refractory prostate cancer in 2007.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The DNA damage response: putting checkpoints in perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Cell cycle checkpoint signaling through the ATM and ATR kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

ERK1 and ERK2 kinases activate hydroxyurea-induced S-phase checkpoint in MCF7 cells by mediating ATR activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

A comparison of BRCA1 nuclear localization with 14 DNA damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

MDC1 is a mediator of the mammalian DNA damage checkpoint

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Histone H2A variants H2AX and H2AZ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Emerging targeted therapies in triple-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The DNA damage response, immunity and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

The DNA damage response: ten years after

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

DNA damage repair pathways in cancer stem cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEXCR.2014.08.016

10.1016/J.YEXCR.2014.08.016

7 January 2021

Identifiers

DOI

1 reference

10 May 2018

1 reference

10 May 2018